Liver-specific inhibition of ChREBP improves hepatic steatosis, hypertriglyceridemia, and insulin resistance, accompanied by downregulation of hepatic expression of lipogenic and gluconeogenetic genes, including those encoding ACC, FAS SCD1, and G6Pase in ob/ob mice [24, 25]. The gene discussed is G6PC1; the disease is fatty liver disease.